GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medy-Tox Inc (XKRX:086900) » Definitions » Additional Paid-In Capital

Medy-Tox (XKRX:086900) Additional Paid-In Capital : ₩148,037 Mil(As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Medy-Tox Additional Paid-In Capital?


Medy-Tox's quarterly additional paid-in capital increased from Jun. 2023 (₩147,870 Mil) to Sep. 2023 (₩147,937 Mil) and increased from Sep. 2023 (₩147,937 Mil) to Dec. 2023 (₩148,037 Mil).

Medy-Tox's annual additional paid-in capital declined from Dec. 2021 (₩113,978 Mil) to Dec. 2022 (₩112,896 Mil) but then increased from Dec. 2022 (₩112,896 Mil) to Dec. 2023 (₩148,037 Mil).

Medy-Tox Additional Paid-In Capital Historical Data

The historical data trend for Medy-Tox's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medy-Tox Additional Paid-In Capital Chart

Medy-Tox Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23,621.75 48,688.19 113,978.01 112,896.30 148,036.73

Medy-Tox Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 112,896.30 132,542.27 147,869.64 147,936.93 148,036.73

Medy-Tox Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Medy-Tox Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Medy-Tox's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Medy-Tox (XKRX:086900) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medy-Tox Inc (XKRX:086900) » Definitions » Additional Paid-In Capital
Comparable Companies
XKRX:048410 XKRX:145020 XKRX:214450 XKRX:141080 XKRX:096530 XKRX:085660 XKRX:016790 XKRX:064550 XKRX:298380 XKRX:005250 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
641-4, Gak-Ri, Ochang-Eup, Cheongwon, KOR, 363885
Website
http://www.medytox.com
Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.

Medy-Tox (XKRX:086900) Headlines

No Headlines